Introduction
Diffuse large B-cell lymphoma (DLBCL) represents the most frequent histological subtype of aggressive non-Hodgkin's lymphoma. [1] [2] Although most DLBCL respond to modern chemotherapy regimens that include an anthracycline and alkylating agents, only half of the patients are alive and disease free at 5 years. [2] [3] [4] [5] These results make the search of potential drug resistance mechanisms particularly important in DLBCL. Widely used prognostic factors (especially those utilized for the International Prognostic Index (IPI) 6 are essentially based on the patient's general condition, disease stage, and lactico deshydrogenase (LDH) serum levels but not on specific biological abnormalities present in DLBCL tumor cells. Those widely used parameters are not directly related to mechanisms of resistance to anticancer agents, and do not represent molecular targets for new therapeutic strategies or anticancer agents.
Recently, several biological abnormalities, including overexpression of bcl-2 or survivin and P53 mutations, have been correlated with poorer outcome in DLBCL. [7] [8] [9] [10] 'Classical' drug-resistance mechanisms, including multidrug resistance protein (mdr), mdr-related protein (mrp), lung-related protein (LRP) and glutathione system, which were extensively studied in acute leukemias, have been the subject of fewer reports in lymphomas, especially DLBCL. [11] [12] [13] [14] [15] [16] [17] [18] [19] Glutathione-S-transferases (GST) are a complex multigene family of enzymes widely evaluated in vitro and in vivo that may detoxify electrophilic xenobiotics such as alkylating agents (for review see Tew 20 ) . GST can sequester drugs by directly binding to alkylating agents and steroids, and can also detoxify free radicals generated by anthracyclines. GST-p overexpression has been associated with resistance to alkylating agents and anthracyclines. 20 Many reports have shown that the glutathione S-transferase p (GST-p) isoenzyme is largely expressed in lymphoid tissues compared to other GST isoenzymes, and is elevated in various cell lines resistant to anticancer agents such as adriamycin, cyclophosphamide, melphalan, and chlorambucil. [21] [22] [23] [24] [25] GST-p has been shown to catalyze the conjugation of glutathione (GSH) to chlorambucil and thiotepa. 26, 27 Transfection of GST-p antisense cDNA increased the sensitivity of a cancer cell line to various anticancer agents including adriamycin, etoposide and melphalan. 28 Furthermore, GST-p expression has been recently correlated with efficacy of alkylating agent-based chemotherapy in head and neck carcinomas, acute myelogenous leukemia, and nonsmall cell lung carcinomas. [29] [30] [31] Little is known about the potential role of GST-p in drug resistance in DLBCL. This led us to study the prognostic value of tumor GST-p expression in 69 DLBCL treated with anthracycline and alkylating agent-based chemotherapy.
Methods

Patients and treatment
We studied GST-p expression in 69 patients with DLBCL (according to the REAL classification), 1 who had adequate histological samples for additional studies. Patients were diagnosed at our institution between 03/92 and 11/99 and were included in the French and Belgian GELA group (groupe d'étude des lymphomes agressifs) trials. All pathological specimens were reviewed by one of us (JB). Staging of the disease included complete physical examination with assessment of the general status; blood counts, LDH level, computed tomography (CT) scans of the chest and abdomen, a bone marrow biopsy, and a lumbar puncture. The disease was then classified according to Ann Arbor classification and to the IPI.
All patients were treated with combination chemotherapy regimens containing an anthracycline and alkylating agents. In all, 33 32 patients were assigned to different consolidation regimen based on the IPI (ie disease stage, age, performance status, LDH serum level). Response to therapy was evaluated when patients had completed chemotherapy, then every 3 months for 24 months, and subsequently every 6 months. Complete remission (CR) was defined as the disappearance of all clinical evidence of disease and normalization of all laboratory values, radiographs, CT scans, and bone marrow biopsy. Partial remission (PR) was defined as a decrease of 75% or more in the sum of the products of the maximal perpendicular diameters of all measured lesions that was maintained for at least 4 weeks. Treatment failure was defined as the absence of CR or PR.
GST-p analysis
Initial biopsy samples of all cases were fixed in formaldehyde (10%), alcohol, formaldehyde, acetic acid (AFA) or Bouin fluid and embedded in paraffin. A large panel of antibodies was used in immunohistochemistry to determine the NHL phenotype. GST-p expression analysis was performed with the Envision rabbit method for GST-p (DAKO K 400) using two commercially available polyclonal antibodies (NCL GST pi Novocastra, Newcastle, UK and GSTPI A 3600 Dako). For the first 32 cases analyzed in this study, the two polyclonal antibodies were evaluated on the same lymphoma samples. No discrepancy between these two antibodies was observed. Therefore, only one polyclonal antibody (NCL GST pi Novocastra, Newcastle) was further studied. GST-p expression defined by localized staining in the cytoplasm or the nucleus of the tumor cells was classified according to the percentage of tumor cells stained. GST-p expression was considered as high when greater than 50% of the tumor cells were stained, moderate when 5-50% tumor cells were stained, and absent when less than 5% tumor cells were stained. These thresholds were prospectively evaluated, as they were simple to test and well tailored for immunohistochemical study. Out of 69 cases assessed, 5/69 (7%) were differently analyzed by the two pathologists when two thresholds were used (higher or lower than 50% tumor cells stained) (93% concordant results). When the three threshold were assessed (less than 5% tumor cells stained, 5-50% tumor cells stained and 450% tumor cells stained), the same concordance was observed (7/69 cases with discrepancies and overall 90% concordant results).
Statistical analysis
The association between GST-p expression and patient's clinical characteristics and response to chemotherapy was analyzed by Fisher's exact test. Prognostic analyses were based on CR rates, freedom from progression (FFP) and overall survival (OS). The time at risk was the difference between the date of the start of initial treatment and the date of the first failure or the date when censored. Patients with progressive disease on therapy were considered as having a time to progression equal to zero. FFP and OS curves were estimated using the product-limit method of Kaplan-Meier and were compared using the log-rank test. Progression, relapse, and death were considered failures for the study of FFP. Factors affecting OS and FFP were assessed by a multivariate regression analysis according to Cox's proportionalhazards regression model. A P-value of less than 0.05 was considered as statistically significant. All calculations were performed with SAS software.
Results
Initial characteristics of the patient population and response to treatment
Initial characteristics of the 69 patients are summarized in Table 1 . Median age was 58 (range 20-95 years) and M/F was 1.1. In all, 41 (59%) patients had stage I/II disease; LDH serum levels were elevated in 25 (36%) patients; performance status (according to the WHO classification) was 0/1 in 64 patients (93%). In total, 45 (65%) patients had an IPI score of 0-1, and 24 (35%) patients had an IPI score of 2-4.
In all, 49 (71%) patients reached CR, 12 (17%) patients reached PR and eight (12%) patients, who did not reach CR or PR, were considered as having progressive disease. With a median follow-up of 58 months (range 12-92), 31 (45%) patients had relapsed and 23 (33%) patients had died. FFP and OS at 5 years for the 69 patients were 52713 and 61713%, respectively.
GST-p expression and its prognostic value
GST-p expression was observed in 42 (61%) of the cases. High expression, that is, in more than 50% lymphoid tumor cells, was present in 20 cases (29%) and low expression, that is, in 5-50% lymphoid tumor cells, in 22 cases (32%). A picture of a case with a high GST-p expression and a case with a low GST-p expression is given in Figure 1 .
CR was achieved in 85% of the patients without GST-p expression, 77% of the patients with low GST-p expression, and 45% of the patients with high GST-p expression (P ¼ 0.03) ( Table 2) . Prognostic value of GST-p expression V Ribrag et al
Since the CR and FFP were similar in DLBCL with no and low GST-p expression (Table 2 and Figure 2 ), cases were grouped into two categories for further analysis: those with high GST-p expression (X50% lymphoid tumor cells expressing GST-p), and those with low GST-p expression (o50% lymphoid tumor cells expressing GST-p).
When these two groups were compared, the CR rate was significantly higher in patients with low GST-p expression than in patients with high GST-p expression (P ¼ 0.005) ( Table 2) . Five-year FFP was 24720% in patients with high GST-p expression compared to 63715% in patients with low GST-p expression (P ¼ 0.0001, Figure 3) . High GST-p expression was associated with a trend for a lower survival: 47724% at 5 years compared to 67716% in patients with low GST-p expression (P ¼ 0.07).
Prognostic value of GST-p expression was also evaluated in patients with IPI index 0-1. Patients with an IPI score of 0-1 and low GST-p expression had a CR rate of 88% compared to 36% in patients with high GST-p expression (P ¼ 0.002). In the patients with an IPI score 0-1, 5-year FFP was 76720% in the patients with low GST-p expression as compared to 14716% in patients with high GST-p expression (Po0.0001, Figure 4) . Fiveyear OS was 78716 and 40732%, respectively (P ¼ 0.01, Figure 5) ; Table 2 ). No difference in CR, FFP, and OS was observed in patients with intermediate and high IPI score (2-4) (n ¼ 24).
When patients aged less than 60 year were analyzed separately (39 patients, only eight of whom had high GST-p expression), GST-p expression remained associated with significantly lower CR rate and FFP (P ¼ 0.01) ( Table 2) .
Univariate and multivariate analysis of prognostic factors
No correlation was found between GST-p expression and other main pretreatment factors, including LDH serum level, age, Ann Arbor stage, and performance status ( Table 1 ). The IPI index (0-1 vs 2-4) was also independent of GST-p expression (P ¼ 0.3). Results of the univariate analysis of prognostic factors for FFP and survival are presented in Table 3 .
Contrary to GST-p expression, the IPI index (0-1 vs 2-4) had no prognostic value for the achievement of CR (P ¼ 0.28) ( Table 3 ) but was correlated with FFP: 36720% of the patients with a high IPI score 2-4 were alive in first remission at 5 years Figure 1 (a) DLBCL with a high GST-p expression showing more than 50% lymphoma cells stained (GSTPI A 3600 Dako), and (b) DLBCL with a low GST-p expression with less than 50% lymphoma cells stained (positive dendritic cells could be used as internal control). Prognostic value of GST-p expression V Ribrag et al compared to 60716% of those with a low IPI score 0-1 (P ¼ 0.04) (Figure 4) . A high IPI score (2-4) was also associated with a trend for lower survival at 5 years: 47723% vs 68716% in patients with a low IPI score of 0-1 (P ¼ 0.07, Figure 5 ). After incorporating IPI and GST-p expression in a multivariate analysis for FFP, GST-p expression remained the only prognostic factor (IPI ¼ 0.18, RR 1.6, 95% confidence interval: 0.8-3.4, GST-p expression ¼ 0.0006, RR 3.5, 95% confidence interval: 1.7-7.2).
Discussion
Drug-resistance mechanisms to anticancer agents in NHL, especially DLBCL, still remain poorly known. The role of the mdr gene (which encodes for P-glycoprotein) has been studied OS of the 45 patients with DLBL and an IPI score 0-1 classsified according to GST-p expression (less than 50%, n ¼ 34 (solid line), and more than 50% tumor cells positive, n ¼ 11 (dashed line)).
Prognostic value of GST-p expression V Ribrag et al only in few series of patients with non-Hodgkin's lymphomas, with inconclusive results. [11] [12] [13] [16] [17] [18] [19] Regarding the other membrane transporters known to play a role in drug resistance, two published studies suggest that MRP plays a minor role in drug resistance in lymphoma and that LRP could have prognostic value but is highly correlated with the IPI index. 14, 15 Other reports have shown that abnormalities of proteins involved in the apoptotic pathways potentially involved in drug resistance such as P53 mutations, a high survivin or bcl-2 expression could be associated to a poor outcome in DLBCL. [7] [8] [9] [10] 33 However, no study of GST-p, another protein involved in drug resistance, had been performed in DLBCL.
In this series of 69 patients, we showed that GST-p was expressed in 61% of DLBCL and was present in more than 50% lymphoid tumor cells in 20 (29%) of the cases. We found that high GST-p expression (in 450% of tumor cells) was correlated with a poor probability of reaching CR, poor FFP, and a poor survival, whereas absent (o5% cells) or moderate (5-50% cells) GST-p expression was associated to more favorable outcome. The prognostic value of GST-p expression remained when the analysis was restricted to patients with IPI 0-1. This was similar to findings made for p53 mutations, where studies showed that the prognostic value of this parameter was still found in low-risk patients. 9 Like for P53 mutations, no correlation between GST-p expression and FFP or survival was observed in patients with an IPI score 2-4 (data not shown). This could be explained by the small number of patients studied (n ¼ 24) or by other parameters related to patients' characteristics rather than tumor cell biology in these patients (such as PS and age 460 years).
The IPI was correlated with a poor FFP (P ¼ 0.03) and a poor survival (P ¼ 0.07) in our 69 patients. The lack of statistically significant difference between IPI 0-1 and 3-4 for OS could have been expected. If we extrapolate the IPI results based on more than 2000 patients to the 69 patients of our study, we have only 40% of probability to obtain a significant difference at 5 years for FFP and survival. 6 Correlation studies and multivariate analysis confirmed that GST-p expression had independent prognostic value in the present series. Indeed, the 'classical' prognostic parameters in DLBCL (advanced clinical stage, unfavorable performance status, age 460 years, elevated LDH values, and IPI score) did not correlate with GST-p expression and did not correlate with CR achievement. Although GST-p expression and IPI score were correlated with FFP in this series, only GST-p expression remained significant in a multivariate analysis for FFP. These results suggest that GST-p expression has a strong predictive value of chemotherapy sensitivity (CR and FFP) compared to the IPI index and could play a role in anticancer agent resistance in DLBCL.
The precise mechanism whereby GST-p is responsible for resistance to anticancer agents is still a matter of debate. 20, 28 Hypotheses based on the physical properties of this conjugating enzyme include GSH conjugation to anticancer drugs, cytosolic sequestration of anticancer drugs by direct binding to GST-p, and chemical reduction of the hydroxyl radicals formed by anthracyclins. It is worth noting that the prognostic value of GST-p expression has already been reported in other human cancers, such as acute myelogenous leukemia, head and neck carcinomas, and nonsmall cell lung carcinoma. [29] [30] [31] The pleiotropic role of the glutathione system could be explained by the presence of GST-p in almost all the human tissues, and drug resistance mediated by GST-p is probably not specific of a tumor type but of anticancer agents metabolism. Recently, new mechanisms underlying GST-p-mediated cellular protection against oxydative stress-induced cell death have been identified. It has been shown that GST-p is involved in the coordinated regulation of stress kinase as reflected by increased nuclear factor kB activities together with suppression of JNK signaling. [34] [35] [36] These observations together with the potential importance of the nuclear factor kB pathway in DLBCL suggest that this drug-resistance mechanism should be further studied in the lymphoma entity.
37 Table 3 Univariate analyses Prognostic value of GST-p expression V Ribrag et al
In conclusion GST-p expression at diagnosis seems to be correlated with the probability of achieving and maintaining CR in DLBCL. The direct role of GST-p in in vivo drug resistance in DLBCL will have to be more precisely evaluated.
